Patent classifications
A61K31/541
1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
Compounds of the formula ##STR00001##
where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
Compounds of the formula ##STR00001##
where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R.sup.1-1-carbonyl)thiazole-2-carboxamide, wherein R.sup.1 is defined in the specification.
TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R.sup.1-1-carbonyl)thiazole-2-carboxamide, wherein R.sup.1 is defined in the specification.
SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Pyrimidine compounds as mTOR and PI3K inhibitors
The present invention relates to pyrimidine compounds of formula (I): ##STR00001##
which are useful in treating mTOR kinase- or PI3K kinase-related diseases.
Pyrimidine compounds as mTOR and PI3K inhibitors
The present invention relates to pyrimidine compounds of formula (I): ##STR00001##
which are useful in treating mTOR kinase- or PI3K kinase-related diseases.
Pyrimidine compounds as mTOR and PI3K inhibitors
The present invention relates to pyrimidine compounds of formula (I): ##STR00001##
which are useful in treating mTOR kinase- or PI3K kinase-related diseases.
COMBINATION THERAPIES
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
The present invention discloses compounds according to Formula I: ##STR00001##
Wherein R.sup.1a, R.sup.1b, R.sup.2, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.